Home >> Pharmaceuticals >> Food & Beverage >>

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2015

Published: May-2015 | Format: PDF | GlobalData | Number of pages: 140 | Code: MRS - 18237

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2015

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2015” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2015. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market.
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 11
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q1 2015 15
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q1 2015 15
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q1 2015 18
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q1 2015 19
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2015 20
2.4.1 AbbVie to Acquire Pharmacyclics for USD21 Billion 20
2.4.2 Actavis Raises USD21 Billion in Public Offering of Senior Notes 21
2.4.3 Pfizer to Acquire Hospira for USD17 Billion 21
2.4.4 UnitedHealth to Acquire Catamaran for USD12.8 Billion 22
2.4.5 Valeant Pharma Acquires Salix Pharma for USD10.9 Billion 22
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 25
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q1 2015 25
3.1.1 Top M&A Deals in Q1 2015 26
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q1 2014 - Q1 2015 27
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q1 2015 28
3.2.1 Top Initial Public Offerings in Q1 2015 29
3.2.2 Top Secondary Offerings in Q1 2015 30
3.2.3 Top PIPE Deals in Q1 2015 30
3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q1 2014-Q1 2015 31
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q1 2014 - Q1 2015 31
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q1 2015 33
3.3.1 Top Venture Financing Deals in Q1 2015 34
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2015 35
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2015 36
3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q1 2014 - Q1 2015 37
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q1 2014 - Q1 2015 38
3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q1 2014 - Q1 2015 39
3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q1 2015 40
3.4.1 Top Private Equity Deals in Q1 2015 41
3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q1 2014 - Q1 2015 42
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2015 43
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2015 43
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q1 2014 - Q1 2015 45
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2015 47
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q1 2015 48
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2015 49
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q1 2015 50
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2014 - Q1 2015 51
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q1 2014 - Q1 2015 53
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q1 2014 - Q1 2015 54
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2014 - Q1 2015 55
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q1 2015 57
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q1 2015 57
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2014 - Q1 2015 59
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q1 2015 60
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q1 2015 61
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q1 2015 61
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q1 2014 - Q1 2015 62
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q1 2014 - Q1 2015 64
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q1 2014 - Q1 2015 66
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q1 2014 - Q1 2015 67
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q1 2014 - Q1 2015 69
6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 71
6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q1 2014 - Q1 2015 71
6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q1 2014 - Q1 2015 73
6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2014 - Q1 2015 74
6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q1 2014 - Q1 2015 76
6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q1 2014 - Q1 2015 77
6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q1 2014 - Q1 2015 78
6.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2014 - Q1 2015 79
7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 80
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q1 2015 80
7.1.1 Oncology - Deals of the Quarter 81
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q1 2015 84
7.2.1 Central Nervous System - Deals of the Quarter 86
7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q1 2015 89
7.3.1 Infectious Disease - Deals of the Quarter 90
7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q1 2015 93
7.4.1 Immunology - Deals of the Quarter 95
7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q1 2015 97
7.5.1 Metabolic Disorders - Deals of the Quarter 98
7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q1 2015 100
7.6.1 Cardiovascular - Deals of the Quarter 101
7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q1 2015 103
7.7.1 Gastrointestinal - Deals of the Quarter 104
7.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q1 2015 106
7.8.1 Dermatology - Deals of the Quarter 107
7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q1 2015 109
7.9.1 Respiratory - Deals of the Quarter 110
7.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q1 2015 112
7.10.1 Ophthalmology - Deals of the Quarter 114
8 Deal Summary by Geography 117
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q1 2015 117
8.1.1 North America - Deals of the Quarter 119
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q1 2015 122
8.2.1 Europe - Deals of the Quarter 123
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q1 2015 125
8.3.1 Asia-Pacific - Deals of the Quarter 126
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q1 2015 128
8.4.1 Rest of the World - Deals of the Quarter 129
9 Pharmaceuticals & Healthcare, Global, Top Advisors 131
9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q1 2014 - Q1 2015 131
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q1 2014 - Q1 2015 133
10 Appendix 135
11 Further Information 137
11.1 Methodology 137
11.2 About GlobalData 138
11.3 Disclosure information 139
11.4 Disclaimer 139

1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q1 2014 - Q1 2015 17
Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q1 2015 19
Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2015 20
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 26
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q1 2015 26
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q1 2014 - Q1 2015 27
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2014 - Q1 2015 29
Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q1 2015 29
Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q1 2015 30
Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q1 2015 30
Table 11: Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q1 2014-Q1 2015 31
Table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2014 - Q1 2015 32
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 34
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q1 2015 34
Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q1 2015 36
Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2014 - Q1 2015 37
Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 38
Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q1 2014 - Q1 2015 39
Table 19: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 41
Table 20: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q1 2015 41
Table 21: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2014 - Q1 2015 42
Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 44
Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 46
Table 24: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2014 - Q1 2015 48
Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2015 48
Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2015 49
Table 27: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q1 2015 50
Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2014 - Q1 2015 52
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2014 - Q1 2015 54
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2014 - Q1 2015 56
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 58
Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2014 - Q1 2015 60
Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q1 2015 60
Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q1 2015 61
Table 35: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q1 2015 61
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 63
Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q1 2014 - Q1 2015 65
Table 38: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2014 - Q1 2015 68
Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2014 - Q1 2015 70
Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q1 2014 - Q1 2015 72
Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q1 2014 - Q1 2015 73
Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2014 - Q1 2015 75
Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q1 2014 - Q1 2015 76
Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q1 2014 - Q1 2015 77
Table 45: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q1 2014 - Q1 2015 78
Table 46: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2014 - Q1 2015 79
Table 47: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 81
Table 48: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 85
Table 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 90
Table 50: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 94
Table 51: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 98
Table 52: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 101
Table 53: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 104
Table 54: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 107
Table 55: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 110
Table 56: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 113
Table 57: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 118
Table 58: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 123
Table 59: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 126
Table 60: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 129
Table 61: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 132
Table 62: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 134
Table 63: Pharmaceuticals & Healthcare, Deals’ Key Financials, Global Acquisition Deals, Q1 2014-Q1 2015 135

1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q1 2014 - Q1 2015 15
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q1 2015 18
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q1 2015 19
Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q1 2014 - Q1 2015 25
Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q1 2014 - Q1 2015 27
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 28
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q1 2014 - Q1 2015 31
Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 33
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q1 2015 35
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q1 2015 36
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2014 - Q1 2015 37
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 38
Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 40
Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2014 - Q1 2015 42
Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 43
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 45
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2014 - Q1 2015 47
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2014 - Q1 2015 51
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2014 - Q1 2015 53
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2014 - Q1 2015 54
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2014 - Q1 2015 55
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 57
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2014 - Q1 2015 59
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 62
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2014 - Q1 2015 64
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q1 2014 - Q1 2015 66
Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q1 2014 - Q1 2015 67
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2014 - Q1 2015 69
Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q1 2014 - Q1 2015 71
Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q1 2014 - Q1 2015 73
Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2014 - Q1 2015 74
Figure 32: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q1 2014 - Q1 2015 76
Figure 33: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q1 2014 - Q1 2015 77
Figure 34: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q1 2014 - Q1 2015 78
Figure 35: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2014 - Q1 2015 79
Figure 36: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 80
Figure 37: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 84
Figure 38: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 89
Figure 39: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 93
Figure 40: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 97
Figure 41: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 100
Figure 42: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 103
Figure 43: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 106
Figure 44: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 109
Figure 45: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 112
Figure 46: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 117
Figure 47: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 122
Figure 48: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 125
Figure 49: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 128
Figure 50: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 131
Figure 51: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2014 - Q1 2015 133

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)1500 View Pricing